Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Non-Current Assets: 2019-2024

Historic Non-Current Assets for Avidity Biosciences (RNA) over the last 6 years, with Dec 2024 value amounting to $21.6 million.

  • Avidity Biosciences' Non-Current Assets rose 789.67% to $168.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $168.2 million, marking a year-over-year increase of 789.67%. This contributed to the annual value of $21.6 million for FY2024, which is 25.26% up from last year.
  • As of FY2024, Avidity Biosciences' Non-Current Assets stood at $21.6 million, which was up 25.26% from $17.2 million recorded in FY2023.
  • Avidity Biosciences' 5-year Non-Current Assets high stood at $21.6 million for FY2024, and its period low was $2.2 million during FY2020.
  • For the 3-year period, Avidity Biosciences' Non-Current Assets averaged around $18.2 million, with its median value being $17.2 million (2023).
  • Its Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 640.50% in 2021, then fell by 3.53% in 2022.
  • Over the past 5 years, Avidity Biosciences' Non-Current Assets (Yearly) stood at $2.2 million in 2020, then soared by 640.50% to $16.4 million in 2021, then decreased by 3.53% to $15.9 million in 2022, then rose by 8.77% to $17.2 million in 2023, then increased by 25.26% to $21.6 million in 2024.